16:52 , Oct 17, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Neuroendocrine tumors Cell culture and mouse studies suggest inhibiting EZH2 could help treat MYCN -driven neuroblastoma. In patients, low tumor expression of a MYCN-induced neuroblastoma gene signature comprising polycomb repressive complex 2 (PRC2) targets...
00:11 , Mar 10, 2017 |  BC Innovations  |  Targets & Mechanisms

Poly drugs for polycomb

In parallel studies, Novartis AG and Abbvie Inc. have reported inhibitors of the epigenetic regulator PRC2 that block the protein by a new mechanism, offering a complement to the inhibitors in the clinic, and more...
01:30 , Mar 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma Cell culture and mouse studies suggest allosteric inhibition of the EED subunit of PRC2 could help treat lymphoma. Screening of small molecule libraries in in vitro activity assays by two independent groups yielded...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Structural analyses of polycomb repressive complex 2 (PRC2) bound to an inhibitor and a mutant histone H3 substrate

Drug platforms TECHNOLOGY: Structural analyses Structural analyses of PRC2 bound to an inhibitor or histone H3 substrate could help guide the development of PRC2 inhibitors for cancer that bypass known mechanisms of resistance. Analysis of...
07:00 , May 19, 2016 |  BC Innovations  |  Tools & Techniques

The long view

While most of the activity in RNA-based therapeutics has focused on small RNAs that can dampen expression of disease-causing proteins, Jeannie Lee has built a career, and a company, on transcripts that are about 10...
07:00 , Apr 14, 2016 |  BC Innovations  |  Product R&D

Clearing the RaNAway

Karen Tkach, Staff Writer  After launching RaNA Therapeutics Inc. in 2011 to exploit the therapeutic potential of long-noncoding RNA (lncRNA), the company has gone where the science led it, and added a second platform that...
07:00 , Sep 11, 2014 |  BC Innovations  |  Targets & Mechanisms

A chromatin target for ALL

A New York University School of Medicine - GlaxoSmithKline plc collaboration has shown that an inhibitor of the chromatin regulator JMJD3 could help treat T cell acute lymphoblastic leukemia. 1 As JMJD3 is upregulated and...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , May 15, 2014 |  BC Innovations  |  Cover Story

Chromatin's rising tide

To capitalize on the full range of possible chromatin targets in and beyond oncology, industry and academia will need to delve deeper into how chromatin regulation is altered in disease, create tools that can reliably...
07:00 , Mar 27, 2014 |  BC Innovations  |  Targets & Mechanisms

Insights into ependymoma

Two independent studies have illuminated the fine molecular details of ependymoma tumors and identified targets for a previously intractable disease. A St. Jude Children's Research Hospital team focused on forebrain ependymomas and identified a fusion...